Three of the four partner centres now sell genetic screening inside a top-tier program, and they are selling three different things under one word. This page separates them, because a predictive risk panel, a hereditary-cancer NGS panel and a personal-traits report are not the same product and do not carry the same weight.
KMI Global, Hanaro and MediOne. Hanshin Medipia does not.
Arrhythmia, hypertrophic cardiomyopathy, familial cerebral small-vessel disease, metabolic bone disease and familial cancer.
MediOne prices a disease-risk prediction panel and a personal-traits report at ≈₩300,000 each.
Whole Body, ≈₩3,000,000, which bundles an 11-gene panel and a MASTOCHECK blood test.
One week is the earliest an imaging slot can be held, and there is no referral step before it.
English report in your hands in about a week. You also get a consultation on preliminary findings on the day of the screening, before you leave.
Programme contents and prices from each partner centre's own foreigner-facing published list, read 2026-08-05: KMI Global, Hanaro Medical Foundation's English site and MediOne's English site. Standalone per-test prices are MediOne's 비급여 (non-covered) posting, the itemised list 의료법 제45조 requires a clinic to publish, read the same day. Scheduling and report turnaround are Meridiko's own operating figures, confirmed 2026-08-06, not a centre's published ones (https://global.kmi.or.kr/examination/foreigner_examination; https://en-mobile.hanaromf.com/program/prog01/prog01_01.jsp; https://en.medionemedicalcenter.com/m1; https://medionemedicalcenter.com/115), measured 2026-08-05.
A hereditary-cancer NGS panel sequences named genes for pathogenic variants and is the only one of the three with established clinical action attached. A disease-risk prediction panel scores common variants for conditions like diabetes or hypertension. A personal-traits report covers things like caffeine metabolism and is entertainment with a laboratory attached.
None of them tells you that you will develop a disease. A negative hereditary-cancer panel does not remove your risk, and a high polygenic score is not a diagnosis. None of them replaces a family history taken properly by a doctor.
Suits: People with a strong family history of cancer, cardiomyopathy or early stroke, for whom a hereditary panel can change surveillance. Hanaro's Platinum is the only partner program that names its panels individually, which is what makes it assessable.
Should not have it: Anyone hoping for reassurance. These panels are better at raising questions than settling them, and a result that needs genetic counselling to interpret is a result you should not receive in a language you do not read fluently or with nobody to discuss it with.
A tumour-marker blood panel measures something in your blood today. A genetic panel measures something that has been true since birth. The first can change next year; the second will not, which is why it is worth doing once and worth doing properly.
Not on any of the three tiers this site prices. Genetic screening appears in KMI Global's Whole Body program, Hanaro's Platinum, and MediOne's Premium program, and MediOne prices two of its panels standalone at ≈₩300,000 each. Which genes are actually sequenced differs between all three, so ask for the gene list rather than the word.
